Skip to main content
Yabao Pharmaceutical Group Co.,Ltd logo

Yabao Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600351 ISIN · CNE000001CM5 LEI · 65560071PKRS4UHMVU53 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,360 across all filing types
Latest filing 2025-05-16 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 600351

About Yabao Pharmaceutical Group Co.,Ltd

http://www.yabao.com.cn

Yabao Pharmaceutical Group Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a specialized portfolio across therapeutic areas including pediatrics, cardiovascular health, and endocrinology. Key offerings include traditional Chinese medicines, chemical drugs, and innovative transdermal patches, such as the Dinggui Erqi Patch. The organization operates integrated production bases and research facilities dedicated to advancing drug delivery systems and biotechnological applications. Its business model emphasizes the modernization of traditional therapies alongside the development of conventional pharmaceuticals to address diverse clinical needs.

Recent filings

Filing Released Lang Actions
亚宝药业集团股份有限公司关于以集中竞价交易方式回购股份的回购报告书
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement from 亚宝药业集团股份有限公司 regarding a share repurchase plan. It includes specifics about the repurchase amount, price limits, funding sources, purpose (to reduce registered capital), implementation procedures, and risk factors. The text explicitly mentions the repurchase will be conducted via centralized bidding on the stock exchange and includes detailed financial impact analysis. This matches the definition of a Transaction in Own Shares (POS) filing, which covers company buyback or sale of its own shares. The document is not a report publication announcement or a regulatory filing, as it contains substantive details about the repurchase plan itself. Therefore, the correct classification is POS with high confidence.
2025-05-16 Chinese
亚宝药业集团股份有限公司2024年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2024 Annual General Meeting Resolution Announcement" for 亚宝药业集团股份有限公司. It details the date and location of the AGM, attendance, voting results on various proposals including the 2024 annual report, board reports, financial statements, profit distribution plan, and other corporate governance matters. It also includes legal opinions confirming the legality and validity of the meeting and resolutions. The document is a formal announcement of the voting results and resolutions passed at the AGM, rather than the full annual report or other detailed reports themselves. The length is about 4651 characters, which is consistent with an announcement rather than a full report. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-05-16 Chinese
亚宝药业集团股份有限公司关于参加山西辖区上市公司2025年投资者网上集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in an investor online collective reception day event organized by regulatory and industry bodies. It mentions the date and time of the event, the platform for participation, and the company executives who will attend. The content focuses on investor communication and interaction rather than presenting financial results or detailed reports. The document length is short (618 characters), and it does not contain financial statements or detailed analysis. It is not a report itself but an announcement of an event related to investor relations. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-05-14 Chinese
亚宝药业集团股份有限公司关于回购股份事项前十名股东持股情况的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement from 亚宝药业集团股份有限公司 regarding the shareholding situation of the top ten shareholders before a share repurchase (buyback) plan. It references a previous announcement about the share repurchase plan and provides detailed shareholding data as of the 2024 annual general meeting record date. The document is short (1015 characters) and focuses on shareholding details related to a share buyback. This fits the definition of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back or selling its own shares. It is not an annual report, earnings release, or other report type, nor is it a mere announcement of a report publication. Therefore, the correct classification is POS with high confidence.
2025-05-12 Chinese
亚宝药业集团股份有限公司2024年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as "2024 年年度股东大会会议资料" which translates to "2024 Annual General Meeting (AGM) Meeting Materials". It contains detailed agenda items for the AGM, including the presentation and review of the 2024 Annual Report, Board of Directors report, Supervisory Board report, financial statements, profit distribution plan, and other shareholder meeting procedures. The content includes meeting instructions, agenda, voting procedures, and detailed reports to be discussed at the AGM. The document is lengthy (15,000 characters) and contains the actual meeting materials, not just an announcement or a brief summary. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting.
2025-05-08 Chinese
亚宝药业集团股份有限公司关于回购股份事项前十名股东持股情况的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from the board of directors of 亚宝药业集团股份有限公司 regarding the shareholding situation of the top ten shareholders prior to a share repurchase plan. It references a previous announcement about the share repurchase plan and provides detailed shareholding data as of a specific date. The content focuses on shareholding details related to a share buyback, not on financial results, management changes, or regulatory filings. The key phrase '回购股份事项前十名股东持股情况的公告' translates to 'Announcement on the shareholding situation of the top ten shareholders before the share repurchase.' This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares. The document length is short and contains specific shareholding data, not a report publication or certification, so it is not RPA or RNS. Therefore, the correct classification is POS with high confidence.
2025-04-29 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.